UroGen Q2 Revenue Beats by 14% on ZUSDURI Surge, Raises Cost Guidance
URGN has more than doubled off its 52-week low of $15.86.
Summary
UroGen delivered a strong Q2 with total revenue of $72.5M, beating consensus by 14%, driven by ZUSDURI's 73% sequential growth and $50.4M in ZUSDURI revenue. Operating income swung to a positive $111K, far ahead of the expected $4.3M loss. The company raised full-year operating expense guidance to $260M-$270M, reflecting investment in the ZUSDURI launch. This follows positive 36-month ZUSDURI data in May and an IND clearance for UGN-501 in July, building a narrative of commercial and pipeline momentum. The stock is trading near its 52-week high, and the beat reinforces the launch trajectory.
At the time of this announcement, URGN was trading at $41.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $15.86 to $43.93. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.